Methods of treating aging-related disorders
Provided herein are methods of treating an aging-related disease or condition in a subject in need thereof, killing or reducing the number of senescent cells in a subject in need thereof, improving the texture and/or appearance of skin and/or hair in a subject in need thereof, and assisting in the treatment of obesity in a subject in need thereof, that include administering to the subject a therapeutically effective amount of one or more natural killer (NK) cell activating agent(s) and/or a therapeutically effective number of activated NK cells.
1. A method of treating a cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide comprising:
(a) a first chimeric polypeptide comprising:
(i) a first target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO: 188;
(ii) a soluble tissue factor domain comprising a sequence that is at least 90% identical to SEQ ID NO: 93; and
(iii) a first domain of a pair of affinity domains, wherein the first domain of the pair of the affinity domains comprises a sequence that is at least 90% identical to SEQ ID NO: 115; and
(b) a second chimeric polypeptide comprising:
(i) a second domain of the pair of affinity domains, wherein the second domain of the pair of affinity domains comprises a sequence that is at least 90% identical to SEQ ID NO: 113; and
(ii) a second target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO: 188,
wherein the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains.
2. A method of killing or reducing the number of senescent cells in a subject having a cancer, the method comprising administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide comprising:
(a) a first chimeric polypeptide comprising:
(i) a first target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO: 188;
(ii) a soluble tissue factor domain comprising a sequence that is at least 90% identical to SEQ ID NO: 93; and
(iii) a first domain of a pair of affinity domains, wherein the first domain of the pair of the affinity domains comprises a sequence that is at least 90% identical to SEQ ID NO: 115; and
(b) a second chimeric polypeptide comprising:
(i) a second domain of the pair of affinity domains, wherein the second domain of the pair of affinity domains comprises a sequence that is at least 90% identical to SEQ ID NO: 113; and
(ii) a second target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO: 188,
wherein the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains.
3. The method of claim 1 , wherein the multi-chain chimeric polypeptide results in a decrease in the activation of a TGF-β receptor.
4. The method of claim 1 , wherein the first target-binding domain and the soluble tissue factor domain directly abut each other in the first chimeric polypeptide.
5. The method of claim 1 , wherein the first chimeric polypeptide further comprises a linker sequence between the first target-binding domain and the soluble tissue factor domain in the first chimeric polypeptide.
6. The method of claim 1 , wherein the soluble tissue factor domain and the first domain of the pair of affinity domains directly abut each other in the first chimeric polypeptide.
7. The method of claim 1 , wherein the first chimeric polypeptide further comprises a linker sequence between the soluble tissue factor domain and the first domain of the pair of affinity domains in the first chimeric polypeptide.
8. The method of claim 1 , wherein the second domain of the pair of affinity domains and the second target-binding domain directly abut each other in the second chimeric polypeptide.
9. The method of claim 1 , wherein second chimeric polypeptide further comprises a linker sequence between the second domain of the pair of affinity domains and the second target-binding domain in the second chimeric polypeptide.
10. The method of claim 1 , wherein the soluble tissue factor domain does not stimulate blood coagulation.
11. The method of claim 1 , wherein the soluble tissue factor domain comprises or consists of a sequence from a wildtype soluble human tissue factor.
12. The method of claim 1 , wherein the cancer is pancreatic cancer.
13. The method of claim 1 , wherein:
the first target-binding domain comprises a sequence that is at least 95% identical to SEQ ID NO: 188;
the soluble tissue factor domain comprises a sequence that is at least 95% identical to SEQ ID NO: 93;
the first domain of the pair of affinity domains comprises a sequence that is at least 95% identical to SEQ ID NO: 115;
the second domain of the pair of affinity domains comprises a sequence that is at least 95% identical to SEQ ID NO: 113; and
the second target-binding domain comprises a sequence that is at least 95% identical to SEQ ID NO: 188.
14. The method of claim 1 , wherein:
the first target-binding domain comprises SEQ ID NO: 188;
the soluble tissue factor domain comprises SEQ ID NO: 93;
the first domain of the pair of affinity domains comprises SEQ ID NO: 115;
the second domain of the pair of affinity domains comprises SEQ ID NO: 113; and
the second target-binding domain comprises SEQ ID NO: 188.
15. The method of claim 1 , wherein:
the first chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO: 236; and
the second chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO: 193.
16. The method of claim 1 , wherein:
the first chimeric polypeptide comprises a sequence that is at least 95% identical to SEQ ID NO: 236; and
the second chimeric polypeptide comprises a sequence that is at least 95% identical to SEQ ID NO: 193.
17. The method of claim 1 , wherein:
the first chimeric polypeptide comprises SEQ ID NO: 236; and
the second chimeric polypeptide comprises SEQ ID NO: 193.
18. The method of claim 2 , wherein the cancer is pancreatic cancer.
19. The method of claim 2 , wherein:
the first target-binding domain comprises a sequence that is at least 95% identical to SEQ ID NO: 188;
the soluble tissue factor domain comprises a sequence that is at least 95% identical to SEQ ID NO: 93;
the first domain of the pair of affinity domains comprises a sequence that is at least 95% identical to SEQ ID NO: 115;
the second domain of the pair of affinity domains comprises a sequence that is at least 95% identical to SEQ ID NO: 113; and
the second target-binding domain comprises a sequence that is at least 95% identical to SEQ ID NO: 188.
20. The method of claim 2 , wherein:
the first target-binding domain comprises SEQ ID NO: 188;
the soluble tissue factor domain comprises SEQ ID NO: 93;
the first domain of the pair of affinity domains comprises SEQ ID NO: 115;
the second domain of the pair of affinity domains comprises SEQ ID NO: 113; and
the second target-binding domain comprises SEQ ID NO: 188.
21. The method of claim 2 , wherein:
the first chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO: 236; and
the second chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO: 193.
22. The method of claim 2 , wherein:
the first chimeric polypeptide comprises a sequence that is at least 95% identical to SEQ ID NO: 236; and
the second chimeric polypeptide comprises a sequence that is at least 95% identical to SEQ ID NO: 193.
23. The method of claim 2 , wherein:
the first chimeric polypeptide comprises SEQ ID NO: 236; and
the second chimeric polypeptide comprises SEQ ID NO: 193.
24. The method of claim 2 , wherein the multi-chain chimeric polypeptide results in a decrease in the activation of a TGF-β receptor.
25. The method of claim 2 , wherein the first target-binding domain and the soluble tissue factor domain directly abut each other in the first chimeric polypeptide.
26. The method of claim 2 , wherein the first chimeric polypeptide further comprises a linker sequence between the first target-binding domain and the soluble tissue factor domain in the first chimeric polypeptide.
27. The method of claim 2 , wherein the soluble tissue factor domain and the first domain of the pair of affinity domains directly abut each other in the first chimeric polypeptide.
28. The method of claim 2 , wherein the first chimeric polypeptide further comprises a linker sequence between the soluble tissue factor domain and the first domain of the pair of affinity domains in the first chimeric polypeptide.
29. The method of claim 2 , wherein the second domain of the pair of affinity domains and the second target-binding domain directly abut each other in the second chimeric polypeptide.
30. The method of claim 2 , wherein second chimeric polypeptide further comprises a linker sequence between the second domain of the pair of affinity domains and the second target-binding domain in the second chimeric polypeptide.
31. The method of claim 2 , wherein the soluble tissue factor domain does not stimulate blood coagulation.
32. The method of claim 2 , wherein the soluble tissue factor domain comprises or consists of a sequence from a wildtype soluble human tissue factor.
33. The method of claim 1 , wherein the cancer is ovarian cancer.
34. The method of claim 1 , wherein the cancer is colorectal cancer.
35. The method of claim 1 , wherein the cancer is breast cancer.
36. The method of claim 2 , wherein the cancer is ovarian cancer.
37. The method of claim 2 , wherein the cancer is colorectal cancer.
38. The method of claim 2 , wherein the cancer is breast cancer.
39. The method of claim 1 , wherein the cancer is hepatocellular carcinoma.
40. The method of claim 2 , wherein the cancer is hepatocellular carcinoma.
41. The method of claim 1 , wherein the cancer is melanoma.
42. The method of claim 2 , wherein the cancer is melanoma.
43. The method of claim 1 , wherein the cancer is gastric cancer.
44. The method of claim 2 , wherein the cancer is gastric cancer.
45. The method of claim 1 , wherein the cancer is urothelial carcinoma.
46. The method of claim 2 , wherein the cancer is urothelial carcinoma.